CDKN2A and prostate carcinoma: This kit has been widely used to investigate the methylation status in studies of breast cancer, prostate cancer, and neuroblastoma 14, 15, 16.The results are concordant with previous reports revealing alterations in the methylation profiles of several genes in patients with oligodendroglial tumors, including TIMP3 17, CDKN2A 17, CDKN2B 18, CDKN1B, PTEN 8, RASSF1A 8, DAPK1 17, ESR1 18, TP73 17, and GSTP1 17.